Mackenzie Financial Corp Sells 61 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Mackenzie Financial Corp lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 56,285 shares of the biopharmaceutical company’s stock after selling 61 shares during the period. Mackenzie Financial Corp’s holdings in Regeneron Pharmaceuticals were worth $49,435,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Meyer Handelman Co. increased its holdings in Regeneron Pharmaceuticals by 11.4% during the 3rd quarter. Meyer Handelman Co. now owns 4,235 shares of the biopharmaceutical company’s stock valued at $3,485,000 after purchasing an additional 435 shares during the period. Stifel Financial Corp increased its holdings in Regeneron Pharmaceuticals by 12.2% during the 3rd quarter. Stifel Financial Corp now owns 31,030 shares of the biopharmaceutical company’s stock valued at $25,537,000 after purchasing an additional 3,385 shares during the period. LPL Financial LLC increased its holdings in Regeneron Pharmaceuticals by 9.3% during the 3rd quarter. LPL Financial LLC now owns 40,733 shares of the biopharmaceutical company’s stock valued at $33,522,000 after purchasing an additional 3,479 shares during the period. Cavalier Investments LLC increased its holdings in Regeneron Pharmaceuticals by 88.6% during the 3rd quarter. Cavalier Investments LLC now owns 4,436 shares of the biopharmaceutical company’s stock valued at $3,651,000 after purchasing an additional 2,084 shares during the period. Finally, Exchange Traded Concepts LLC increased its holdings in Regeneron Pharmaceuticals by 32.7% during the 4th quarter. Exchange Traded Concepts LLC now owns 4,954 shares of the biopharmaceutical company’s stock valued at $4,351,000 after purchasing an additional 1,221 shares during the period. Institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on REGN shares. StockNews.com upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, April 12th. Barclays upped their target price on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a report on Tuesday, January 23rd. Morgan Stanley upped their target price on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a report on Wednesday, March 13th. Royal Bank of Canada reiterated an “outperform” rating and set a $1,189.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 9th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $925.00 target price on shares of Regeneron Pharmaceuticals in a report on Monday. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $970.57.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the sale, the executive vice president now owns 48,306 shares in the company, valued at approximately $46,203,239.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, EVP Andrew J. Murphy sold 5,783 shares of the firm’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the transaction, the executive vice president now owns 48,306 shares in the company, valued at $46,203,239.82. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $982.05, for a total value of $98,205.00. Following the transaction, the director now owns 18,282 shares of the company’s stock, valued at approximately $17,953,838.10. The disclosure for this sale can be found here. In the last quarter, insiders sold 13,729 shares of company stock worth $13,124,641. Corporate insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.5 %

NASDAQ:REGN opened at $894.14 on Wednesday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. The firm has a market capitalization of $98.14 billion, a price-to-earnings ratio of 25.73, a price-to-earnings-growth ratio of 2.62 and a beta of 0.11. Regeneron Pharmaceuticals, Inc. has a one year low of $684.80 and a one year high of $998.33. The business has a fifty day moving average price of $955.94 and a 200-day moving average price of $890.45.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The business had revenue of $3.43 billion during the quarter, compared to analyst estimates of $3.29 billion. During the same quarter in the prior year, the business posted $10.96 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up .6% compared to the same quarter last year. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.18 EPS for the current year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.